A Phase 4 interventional study of Atogepant and Ubrogepant in Episodic Migraine, sponsored by AbbVie. Completed at 37 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 15th largest by enrollment, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 12th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 31st largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2022, is one of 5 in phase 4, and was the 39th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess the safety and efficacy of the combination use of ubrogepant for the acute treatment of migraine headache in participants taking atogepant once daily for preventive treatment of migraine.
Ubrogepant is an approved drug for the acute treatment of migraine. Atogepant is an approved drug for the preventive treatment of migraine. Approximately 235 adult participants with EM will be enrolled in approximately 45 sites in the United States.
Participants will receive oral atogepant tablets once daily (QD) for 12 weeks followed by continued atogepant treatment with ubrogepant tablets taken as needed for the next 12 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive atogepant for 12 weeks followed by atogepant + ubrogepant for 12 weeks.
Drug: Atogepant · Drug: Ubrogepant
Oral Tablet
Also known as: QULIPTA
Oral Tablet
Also known as: UBRELVY
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. A treatment-emergent adverse event (TEAE) is an AE that occurs or worsens after receiving investigational study drug.
Time frame: From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.
Time frame: Up to approximately 28 weeks
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Time frame: Up to approximately 24 weeks
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Time frame: Up to approximately 28 weeks
Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period
C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.
Time frame: Week 1 to Week 12 for Safety Population 1; Week 12 to Week 24 for Safety Population 2
Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS) During the 4-Week Safety Follow-Up Period
C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.
Time frame: From last dose of study drug to 4 weeks after last dose of study drug. Overall median time on atogepant treatment was 85 days.
| Milestone | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| Started | 262 | 0 |
| Completed | 221 | 0 |
| Not completed | 41 | 0 |
| Milestone | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| Started | 0 | 218 |
| Completed | 0 | 203 |
| Not completed | 0 | 15 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. A treatment-emergent adverse event (TEAE) is an AE that occurs or worsens after receiving investigational study drug.
| Participants | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 130 | 94 |
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.
| participants | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| Erythrocytes, Hematology (10^12/L): < 0.9 * LLN | 3 | 3 |
| Hematocrit (fraction of 1): < 0.9 * LLN | 5 | 2 |
| Hemoglobin (g/L): < 0.9 * LLN | 6 | 3 |
| Leukocytes, Hematology (10^9/L): < 0.9 * LLN | 3 | 7 |
| Lymphocytes (10^9/L): < 0.7 * LLN | 1 | 0 |
| Lymphocytes (10^9/L): > 1.3 * ULN | 0 | 1 |
| Neutrophils (10^9/L): < 0.7 * LLN | 4 | 1 |
| Neutrophils (10^9/L): > 1.3 * ULN | 4 | 1 |
| Platelets (10^9/L): < 0.5 * LLN | 0 | 1 |
| Alanine Aminotransferase (U/L): ≥ 3.0 * ULN | 3 | 0 |
| Aspartate Aminotransferase (U/L): ≥ 3.0 * ULN | 1 | 0 |
| Bicarbonate (mmol/L): < 0.9 * LLN | 5 | 2 |
| Bilirubin, Chemistry (µmol/L): ≥ 1.5 * ULN | 2 | 2 |
| Calcium (mmol/L): < 0.9 * LLN | 1 | 0 |
| Creatine Kinase (U/L): > 2.0 * ULN | 9 | 5 |
| Glucose, Chemistry (mmol/L): < 0.8 * LLN | 2 | 2 |
| Glucose, Chemistry (mmol/L): > 2.0 * ULN | 2 | 1 |
| Lactate Dehydrogenase (U/L): > 3.0 * ULN | 1 | 0 |
| Phosphate (mmol/L): < 0.9 * LLN | 1 | 1 |
| Phosphate (mmol/L): > 1.1 * ULN | 3 | 0 |
| Potassium (mmol/L): < 0.9 * LLN | 0 | 1 |
| Potassium (mmol/L): > 1.1 * ULN | 5 | 4 |
| Protein, Chemistry (g/L): < 0.9 * LLN | 3 | 2 |
| Glucose, Urinalysis: At least 1+ | 4 | 0 |
| Protein, Urinalysis: At least 1+ | 38 | 39 |
12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
| participants | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| PR Interval (msec): ≥ 250 | 0 | 0 |
| QRS Interval (msec): ≥ 150 | 0 | 1 |
| QTcB (msec): > 500 | 0 | 0 |
| QTcB (msec): Increase of > 60 | 0 | 0 |
| QTcF (msec): > 500 | 0 | 0 |
| QTcF (msec): Increase of > 60 | 0 | 0 |
PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
| participants | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| Sitting Systolic Blood Pressure (mmHg): ≤ 90 and Decrease of ≥ 20 | 4 | 2 |
| Standing Systolic Blood Pressure (mmHg): ≥ 180 and Increase of ≥ 20 | 1 | 0 |
| Standing Systolic Blood Pressure (mmHg): ≤ 90 and Decrease of ≥ 20 | 2 | 2 |
| Sitting Diastolic Blood Pressure (mmHg): ≥ 105 and Increase of ≥ 15 | 1 | 1 |
| Standing Diastolic Blood Pressure (mmHg): ≥ 105 and Increase of ≥ 15 | 5 | 3 |
| Standing Diastolic Blood Pressure (mmHg): ≤ 50 and Decrease of ≥ 15 | 1 | 1 |
| Sitting Pulse Rate (bpm): ≥ 120 and Increase of ≥ 15 | 0 | 1 |
| Sitting Pulse Rate (bpm): ≤ 50 and Decrease of ≥ 15 | 4 | 2 |
| Standing Pulse Rate (bpm): ≥ 120 and Increase of ≥ 15 | 1 | 2 |
| Standing Pulse Rate (bpm): ≤ 50 and Decrease of ≥ 15 | 1 | 0 |
| Weight (kg): Increase of ≥ 7% | 5 | 7 |
| Weight (kg): Decrease of ≥ 7% | 16 | 28 |
| Orthostatic Systolic Blood Pressure (mmHg): ≤ -20 | 12 | 7 |
| Orthostatic Diastolic Blood Pressure (mmHg): ≤ -15 | 6 | 10 |
| Orthostatic Pulse Rate (bpm): ≥ 25 | 10 | 7 |
C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.
| participants | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| Suicidal Ideation | 0 | 2 |
| Suicidal Behavior | 0 | 1 |
C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and suicidal behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.
| participants | Atogepant 60 mg (Period 1) |
|---|---|
| Suicidal Ideation During Follow-Up Period | 1 |
| Suicidal Behavior During Follow-Up Period | 0 |
Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent to the end of the study. The median time on follow-up was 75.5 days from Visit 1 (Week -1) through end of Period 1 and 206 days from baseline through end of Period 2.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atogepant 60 mg (Period 1) | 0/263 (0%) | 1/263 (0.4%) | 66/263 (25.1%) |
| Atogepant 60 mg + Ubrogepant 100 mg (Period 2) | 0/218 (0%) | 1/218 (0.5%) | 15/218 (6.9%) |
| Event | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| MYELOPATHYNervous system disorders | 0/263 | 1/218 |
| URETEROLITHIASISRenal and urinary disorders | 1/263 | 0/218 |
| Event | Atogepant 60 mg (Period 1) | Atogepant 60 mg + Ubrogepant 100 mg (Period 2) |
|---|---|---|
| COVID-19Infections and infestations | 23/263 | 7/218 |
| FATIGUEGeneral disorders | 17/263 | 3/218 |
| NAUSEAGastrointestinal disorders | 16/263 | 2/218 |
| DECREASED APPETITEMetabolism and nutrition disorders | 15/263 | 2/218 |
| CONSTIPATIONGastrointestinal disorders | 14/263 | 2/218 |
Overall safety population included all participants who received at least 1 dose of study drug. 263 participants were enrolled, but one participant withdrew consent prematurely discontinuing from the study before receiving study drug.
| Age, Customized(Participants) | All Subjects |
|---|---|
| Age Group — < 20 years | 0 |
| Age Group — 20 to 29 years | 43 |
| Age Group — 30 to 39 years | 60 |
| Age Group — 40 to 49 years | 71 |
| Age Group — 50 to 59 years | 53 |
| Age Group — 60 to 69 years | 33 |
| Age Group — ≥ 70 years | 2 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 214 |
| Male | 48 |
| Ethnicity (NIH/OMB)(Participants) | All Subjects |
|---|---|
| Hispanic or Latino | 27 |
| Not Hispanic or Latino | 235 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Subjects |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 8 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 44 |
| White | 205 |
| More than one race | 4 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Mar 2022 to primary completion in Apr 2023, 12 months.
Results were first posted in Oct 2024, 1 year 6 months after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 12 months is below that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atogepant · Ubrogepant